BrightHeart, an AI leader in obstetric and pediatric cardiology technology, has received FDA 510(k) clearance for its first AI software, designed to revolutionize prenatal fetal heart ultrasound evaluations. This marks a significant breakthrough in detecting congenital heart defects (CHDs), the most common birth defect, affecting 1 in 100 newborns. Early and accurate detection is crucial for life-saving interventions, and BrightHeart’s AI software enhances the ability to identify CHD-related abnormalities, particularly in resource-limited settings.
Cécile Dupont, CEO of BrightHeart, highlighted that fetal heart assessments are highly technical, and the AI solution helps clinicians detect abnormalities earlier, while also providing confidence in confirming normal results, which reassures expectant families.
The software integrates smoothly into existing workflows, reducing the workload for overburdened sonographers and OB/GYNs. By automating key evaluation steps, it enhances efficiency and accuracy, especially in resource-constrained environments.
Founded two years ago by pediatric cardiologists Dr. Marilyne Levy and Dr. Bertrand Stos, BrightHeart has achieved this FDA clearance in record time, demonstrating the power of its AI technology and the team's dedication. Now positioned for U.S. commercial launch, BrightHeart aims to scale operations and introduce its technology to clinics and hospitals nationwide.
Chairman Michael Butchko emphasized that BrightHeart is poised to address prenatal care challenges like resource shortages and workforce gaps, aiming to improve prenatal care outcomes for clinicians and families alike.
Click here to read the original news story.